Member Info for _Mr_Big

Bought more - let's hope it's not a falling knife.

PS pmjh's done the right thing - best not to look at sp for a few weeks.

There could be a big overhang from the placing and there could be some sells from traders on RNS, but this is bullsh.t price.
Will hold until the end if I have to, but not happy about it.

"We are scaling up the manufacture to be able to produce tens of, if not hundreds of thousands of treatments per month".

I take it that's the manufacturing update. I thought we were supposed to be producing 100s of thousands a month from Jan 2021.

Don't think yanks will be pre-ordering - more likely to be a licensing agreement with USA making all the doses themselves, with SNG just receiving royalties. And since we are in Activ-2, I imagine the pricing has already been agreed, perhaps conditional on trial results.

From memory, easier to produce and can be plugged into mechanical ventilators, but only 70% as efficient. Doubling the dose gives us 140% dosage compare to phase 2. I don't think this can reduce effectiveness of the treatment, if anything, make it even more effective, but at the risk of more side effects (from memory, we've had none whatsoever with P2 dose).

Mrs lived in Brighton for a few years back when we were young.

Brighton peer's good fun on a sunny day.

wtf do they teach kids at school these days? Look down - if there's a willy, then you're a boy. If not you're a girl.

wtf is a "cis"?

First macosta, then eva, now pmjh... The best of us are leaving this board in search of a better life.

The main reason I even bother checking this board every day was to read what pmjh has managed to dig up.

No faces, but plenty of Rsholes, Har.

This would have breached £3, maybe £4 if this RNS landed back in August. Since then we have found out that the bug likes to mutate and the vax programme won't be delivered by Jan 2021 globally.

The SP is somewhere between £3 and £4, it just doesn't know it yet.

pmjh, I take my hat off to you sir.

And there's no need for you to eat it lol.

Charts, shmarts. I just pick a company name and take a punt.

Worked with Synairgen.

Scinv - your logic is b.llocks mate.
1) There is no regard for IP in Infringistan, hence we need to sell ANG001 at £10 a fix in countries that do care about IP. This makes no sense.
2) Nobody else has made a move into inhaled ifnb (a large pharma could do a trial and get an eua in under 6 months for under £60m, which is peanuts for them) because there's no profit in it, but as soon as we get our P3, every man and his dog will flood the market with off-brand inhaled ifn at £8 per fix. This makes no sense.

Not going to argue about our IP position or the science behind SNG001 as I know nothing about them, but your commercial thinking is way off/borderline delusional.

Last but not least, RM outlined SNG strategy back in October - why are you still holding if you think the core company strategy is *******s?

"Mr_Big - because there is not much profit to be made for big pharma"
What about small pharma? I'm not buying it.
How much profit is being made on aldi/tesco/sainsbury's-branded 60p-a-packet aspirin? I'm no good at maths but it can't be more than £1 per sale, surely ;) Yet it's available in every shop&pharmacy anywhere in the world.

Scinv - not sure I'm following your logic any more, but here's a question: if everyone can produce inhaled ifn treatments at £20 a pop, why have we not seen hundreds of pharmas kicking off trials last year, or at least after the lancet publication?

I bet you Pamela's looking at google trends, wondering why her searches have gone up 600% this morning.

There were a few keen "googlers" a few months ago, but nothing ever came out of it. I'm sceptical about this technique - we can all google Pamela Anderson but it doesn't mean any of us are going to find her in the kitchen cooking us breakfast tomorrow morning.